secwatch.observer — SEC 8-K summary
======================================

Issuer:     EAGLE PHARMACEUTICALS, INC. (—)
CIK:        0000827871
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001104659-24-116329
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eagle Pharmaceuticals appoints Christopher Krawtschuk as CFO effective Nov 11, 2024
--------------------------------------------------------------------------------

- Christopher Krawtschuk named CFO, effective Nov 11; Steven Ratoff steps down as interim CFO, remains director.
- Krawtschuk previously CFO/treasurer at bluebird bio, CFO at Jubilant Pharma, U.S. CFO at Morphosys.
- Offer letter: $525k base salary, 50% target bonus, $150k signing bonus, 100k performance-vesting RSUs tied to listing and SEC filings.
- Shares trade on OTC Expert Market since Oct 4; 13,023,123 shares outstanding as of Oct 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/827871/000110465924116329/0001104659-24-116329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/827871/000110465924116329/tm2427095d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-116329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer